Gan & Lee Pharmaceuticals Management

Management criteria checks 3/4

Gan & Lee Pharmaceuticals' CEO is Kai Du, appointed in Jul 2020, has a tenure of 3.83 years. directly owns 0.02% of the company’s shares, worth CN¥5.75M. The average tenure of the management team and the board of directors is 3.8 years and 4.1 years respectively.

Key information

Kai Du

Chief executive officer

CN¥1.0m

Total compensation

CEO salary percentage	n/a
CEO tenure	3.8yrs
CEO ownership	0.02%
Management average tenure	3.8yrs
Board average tenure	4.1yrs

Recent management updates

Recent updates

CEO

Kai Du (46 yo)

3.8yrs

Tenure

CN¥1,048,800

Compensation

Mr. Kai Du is General Manager of Gan & Lee Pharmaceuticals. since July 20, 2020 and has been its Director since April 26, 2019.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Gan Zhongru	Founder & Chairman	26.3yrs	CN¥457.20k	34.85% CN¥ 9.9b
Kai Du	GM & Director	3.8yrs	CN¥1.05m	0.020% CN¥ 5.8m
Cheng Sun	CFO & Deputy GM	3.8yrs	CN¥694.70k	0.020% CN¥ 5.8m
Weiqiang Song	Deputy GM & Director	8.3yrs	CN¥958.90k	0.020% CN¥ 5.8m
Cheng Xing	Deputy General Manager	3.8yrs	CN¥761.30k	0.020% CN¥ 5.8m
Zifei Yuan	Deputy General Manager	3.8yrs	CN¥757.10k	0.020% CN¥ 5.8m
Rong Zou	Secretary	6.4yrs	CN¥690.30k	0.020% CN¥ 5.8m

3.8yrs

Average Tenure

41yo

Average Age

Experienced Management: 603087's management team is considered experienced (3.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Gan Zhongru	Founder & Chairman	26.3yrs	CN¥457.20k	34.85% CN¥ 9.9b
Kai Du	GM & Director	5.1yrs	CN¥1.05m	0.020% CN¥ 5.8m
Weiqiang Song	Deputy GM & Director	8.7yrs	CN¥958.90k	0.020% CN¥ 5.8m
Jiao Jiao	Director	3.2yrs	CN¥909.20k	0.020% CN¥ 5.8m
Lei Yin	Director	3.2yrs	CN¥942.60k	0.020% CN¥ 5.8m
Wei Chen	Director	2.7yrs	CN¥849.70k	0.020% CN¥ 5.8m
Yanqing He	Independent Director	5.1yrs	CN¥67.40k	no data
Guojun Zheng	Independent Director	5.1yrs	CN¥67.40k	no data
Yi Wang	Supervisor	3.2yrs	no data	no data
Tao Zhang	Chairman of the Board of Supervisors	2.7yrs	no data	no data
Jiaxin Wang	Supervisor	5.1yrs	no data	no data
Zengyi Chang	Independent Director	2yrs	CN¥44.50k	no data

4.1yrs

Average Tenure

43.5yo

Average Age

Experienced Board: 603087's board of directors are considered experienced (4.1 years average tenure).

Gan & Lee Pharmaceuticals Management

Management criteria checks 3/4

Key information

Recent management updates

Gan & Lee Pharmaceuticals., Annual General Meeting, May 16, 2024

Less than half of directors are independent

Recent updates

Gan & Lee Pharmaceuticals., Annual General Meeting, May 16, 2024

First quarter 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.09 in 1Q 2023)

Gan & Lee Pharmaceuticals. to Report Q1, 2024 Results on Apr 25, 2024

Gan & Lee Pharmaceuticals. to Report Fiscal Year 2023 Results on Apr 25, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: CN¥0.23 (vs CN¥0.39 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.55 loss in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.09 (vs CN¥0.20 in 1Q 2022)

Gan & Lee Pharmaceuticals.(XSSC:603087) dropped from FTSE All-World Index (USD)

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.39 loss per share (vs CN¥0.90 profit in 3Q 2021)

Gan & Lee Pharmaceuticals. announced that it expects to receive CNY 813.6 million in funding

Second quarter 2022 earnings released: CN¥0.55 loss per share (vs CN¥0.32 profit in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.34 in 1Q 2021)

Gan & Lee Pharmaceuticals Co., Ltd. Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for a Novel Glucagon-Like Peptide-1 Analogue, GZR18

Third quarter 2021 earnings released: EPS CN¥0.90 (vs CN¥0.70 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.34 in 2Q 2020)

Gan & Lee Pharmaceuticals Co., Ltd. Announces Positive Phase 1 Clinical Trial Results at the 81st Scientific Sessions of the American Diabetes Association

First quarter 2021 earnings released: EPS CN¥0.34 (vs CN¥0.24 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥2.31 (vs CN¥2.31 in FY 2019)

New 90-day low: CN¥121

FDA Grants Fast Track Designation for Gan & Lee Pharmaceuticals Co., Ltd.'s GLR2007, for the Treatment of Patients with Glioblastoma

Investor sentiment improved over the past week

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age